'Humbled' Amyris Scales Back Expansions Plans

Synthetic biology firm Amyris (Emeryville, CA) says operational challenges have forced it to re-evalutate its commercialization strategy and scale back ambitious 2012 production targets for biobased farnesene. The company will focus on higher-value opportunities in specialty chemicals for the versatile C15 hydrocarbon, leaving higher-volume base oils and biofuels efforts under previously-established joint ventures with Total and Cosan.  “2011 was a year of accomplishment and a year of learning,  says CEO John Melo. Amyris opened three...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers